It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and a surge in mergers and acquisitions (M&A) activity were expected to keep the sector going in 2024, but a slowdown in collaboration deals despite a drop in interest rates and market volatility hit hard.Nonetheless, given the continuous need for innovative medical treatments, irrespective of the state of the econ ...